TI
SCLN

Trexquant Investment’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Trexquant Investment’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-46,629
Closed -$504K – 1475
2016
Q4 		$504K Buy
+46,629
New +$466K 0.08% 432
2016
Q2 		– Sell
-54,537
Closed -$600K – 1255
2016
Q1 		$600K Buy
+54,537
New +$485K 0.07% 473
2015
Q3 		– Sell
-48,900
Closed -$480K – 1416
2015
Q2 		$480K Sell
48,900
-10,057
-17% -$91.6K 0.05% 637
2015
Q1 		$522K Buy
58,957
+42,157
+251% +$336K 0.05% 667
2014
Q4 		$147K Buy
+16,800
New +$136K 0.03% 843

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Trexquant Investment's SCLN Position: Q1 2017 in Review

Trexquant Investment sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2017, closing a stake of 46,629 shares — an estimated $504K sold.

Trexquant Investment first reported a position in SCLN in Q4 2014 and held it in 5 quarters. The position peaked at $600K in Q1 2016. 136 funds tracked by Wall St. Rank hold SCLN as of Q1 2017.

  • Trexquant Investment reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Trexquant Investment sold 46,629 Sciclone Pharmaceuticals Inc shares in Q1 2017, an estimated $504K.
  • Trexquant Investment first reported a position in Sciclone Pharmaceuticals Inc in Q4 2014 and held it in 5 quarters.
  • Trexquant Investment's Sciclone Pharmaceuticals Inc position peaked at $600K in Q1 2016.
  • 136 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2017.

Based on Trexquant Investment's 13F filing for Q1 2017, filed 9 May 2017.